These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 8976257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
    Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H.
    Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
    [Abstract] [Full Text] [Related]

  • 4. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB.
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization.
    Qian J, Jenkins RB, Bostwick DG.
    Urology; 1995 Dec; 46(6):837-42. PubMed ID: 7502426
    [Abstract] [Full Text] [Related]

  • 12. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies.
    Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB.
    Cancer Res; 1994 Jul 01; 54(13):3574-9. PubMed ID: 8012984
    [Abstract] [Full Text] [Related]

  • 13. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.
    Cadeddu JA, Partin AW, Epstein JI, Walsh PC.
    Urology; 1997 Aug 01; 50(2):251-5. PubMed ID: 9255297
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma.
    Kibel AS, Faith DA, Bova GS, Isaacs WB.
    J Urol; 2000 Jul 01; 164(1):192-6. PubMed ID: 10840458
    [Abstract] [Full Text] [Related]

  • 19. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization.
    Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Löhrs U.
    Cancer Res; 1994 Aug 15; 54(16):4472-80. PubMed ID: 8044798
    [Abstract] [Full Text] [Related]

  • 20. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A, Varga Z, Von Knobloch R.
    J Urol; 2002 Apr 15; 167(4):1681-6. PubMed ID: 11912387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.